News

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients
Capricor shares four-year data showing Deramiocel slowed DMD progression and preserved function, with maintained safety in long-term use.
Capricor falls after long-term trial data for Duchenne therapy
Capricor Therapeutics (NASDAQ:CAPR) lost ~15% on Friday after the cell therapy developer posted long-term data from an ...
Stocktwits on MSN22h
Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data
Shares of Capricor Therapeutics (CAPR) tumbled 16% on Friday morning following reports that Nicole Verdun, director of the ...
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Skeletal muscle disease progression continues to slow with extended treatment (PUL v2.0) ...
Capricor Therapeutics stock plunges after key FDA officials placed on leave
This leadership vacuum follows another significant departure at the FDA. Peter Marks, former head of the Center for Biologics Evaluation and Research who worked closely with Verdun on establishing new ...